Ho, Stephanie L.
Niu, Fang
Pola, Suresh
Velayos, Fernando S.
Ning, Xian
Hui, Rita L. http://orcid.org/0000-0003-0014-2431
Article History
First Online: 26 February 2020
Change Date: 6 April 2020
Change Type: Correction
Change Details: The article Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study, written by Stephanie L. Ho, Fang Niu, Suresh Pola, Fernando S. Velayos, Xian Ning and Rita L. Hui, was originally published electronically on 26 February 2020 without open access.
Compliance with Ethical Standards
:
: No funding was provided to support this research study.
: The authors, Stephanie L. Ho, Fang Niu, Suresh Pola, Fernando S. Velayos, Xian Ning, and Rita L. Hui, declare that they have no potential conflicts of interest that might be relevant to the contents of this article.
: The study protocol was reviewed and approved by the Institutional Review Boards of Kaiser Permanente Northern California and Kaiser Permanente Southern California. Informed consent was waived for the study.
: All authors participated in drafting or revising the manuscript, approved the final version of the paper, and agree to be accountable for all aspects of the work. RH is the guarantor for the overall content.